Actinogen Medical Limited

Actinogen Med Ltd.'s next confirmed earnings release is scheduled for February 24, 2027.

As of June 30, 2026, Actinogen Med Ltd. has 3.72B shares outstanding.

As of June 30, 2026, Actinogen Med Ltd. maintains a current ratio of 3.45, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.38, indicating elevated leverage, while an interest coverage ratio of -59.44 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Actinogen Med Ltd. posted a negative return on equity (ROE) of -77.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -56.92, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Actinogen Med Ltd.'s stock has gained approximately 40.00% over the past 52 weeks.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -19.17M, while operating income came in at -19.46M.

As of June 30, 2026, Actinogen Med Ltd. holds 11.58M in cash and equivalents against 3.31M in total debt, resulting in a net debt position of -8.39M. Total book value stands at 14.79M, with working capital of 13.72M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Actinogen Med Ltd.'s most recent stock split took place on May 9, 2024.